Table 1.
Clinical and demographic characteristics of the study population
| Characteristics | Population with a BMI < 30 kg/m2 (563 cycles of biological therapy) | Population with a BMI ≥ 30 kg/m2 (143 cycles of biological therapy) | P-value |
|---|---|---|---|
| Male sex | 319 (56.6%) | 100 (69.9%) | 0.003 |
| Age (years) | 53.56 ± 14.55 | 55.06 ± 12.71 | NS |
| Weight (kg) | 72.43 ± 13.31 | 100.14 ± 12.80 | 0.001 |
| Psoriasis duration (months) | 23.11 ± 14.46 | 25.46 ± 13.21 | NS |
| Psoriatic arthritis | 191 (34.0%) | 59 (41.2%) | NS |
| Previous therapies | |||
| Cyclosporine | 311 (55.2%) | 48 (33.6%) | 0.001 |
| Acitretin | 82 (14.6%) | 12 (8.4%) | 0.001 |
| Methotrexate | 219 (38.9%) | 59 (41.3%) | NS |
| Biologics | 249 (44.2%) | 59 (41.3%) | 0.02 |
| Baseline PASI | 15.1 | 17.2 | 0.05 |
| Biological therapy | |||
| Adalimumab | 129 (22.9%) | 45 (31.5%) | NS |
| Etanercept | 121 (21.5%) | 25 (17.5%) | NS |
| Ixekizumab | 105 (18.7%) | 18 (12.6%) | NS |
| Secukinumab | 108 (19.2%) | 14 (9.8%) | NS |
| Ustekinumab | 100 (17.8%) | 41 (28.7%) | NS |
Values are expressed as mean ± SD or n (%)
BMI body mass index, NS not significant, PASI Psoriasis Area and Severity Index